Galectin Therapeutics Inc. (GALT)

[BelizeBeachTrader]

MLV did not raise the price target still at $20.00


Quote:

In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on Galectin Therapeutics (NASDAQ: GALT).

In the report, MLV & Co noted, “Albeit from 8 patients, an abundance of data support the safety and positive effects of GR-MD-02 on the major pathological processes observed in NASH. Next steps include dosing at 4mg/kg, adding FibroScan, an FDA-approved ultrasonic measure of liver tissue elasticity, to cohort 2 protocol. We continue to expect positive results in cohort 2 (expected Jul-Aug 2014).”

Galectin Therapeutics closed on Monday at $15.31.

http://m.benzinga.com/article/4435858?utm_referrer=http%3A%2F%2Fnews.google.com%2F